| 1/19/2021 |
Withings Joins Decentralized Trials & Research Alliance (DTRA) To Democratize And Accelerate Clinical Trials |
PR Newswire |
... trials and research. The "Decentralized Trials & Research Alliance ( DTRA )," which launched December 10th, 2020 , plans to unite industry stakeholders, including healthcare companies, regulators, patient groups and research organizations with a singular mission to make clinical trial participation widely accessible by advancing policies, research practices and new technologies in decentralized clinical research."We've built the largest ecosystem of clinically-validated connected health devices available with the aim to provide unparalleled heath ... |
| 1/13/2021 |
NurseNow Staffing Joins Decentralized Trials & Research Alliance (DTRA) To Democratize And Accelerate Clinical Trials | Business & Finance | heraldchronicle.com |
PR Newswire |
... decentralized clinical trials and research. The "Decentralized Trials & Research Alliance ( DTRA )," which launched December 10th, 2020, unites industry stakeholders, including healthcare companies, regulators, patient groups, and research organizations with a singular mission to make clinical trial participation widely accessible by advancing policies, research practices and new technologies in decentralized clinical research."The Decentralized Trials & Research Alliance (DTRA) is exactly the type of collaborative organization that will provide the much-needed ... |
| 1/13/2021 |
NurseNow Staffing Joins Decentralized Trials & Research Alliance (DTRA) To Democratize And Accelerate Clinical Trials |
Business Insider |
... decentralized clinical trials and research. The "Decentralized Trials & Research Alliance ( DTRA )," which launched December 10th, 2020 , unites industry stakeholders, including healthcare companies, regulators, patient groups, and research organizations with a singular mission to make clinical trial participation widely accessible by advancing policies, research practices and new technologies in decentralized clinical research."The Decentralized Trials & Research Alliance (DTRA) is exactly the type of collaborative organization that will provide the much-needed ... |
| 1/12/2021 |
NeuroRx, Relief, and Quantum Leap announce the inclusion of ZYESAMI in the I-SPY COVID-19 Trial |
worldpharmatoday.com |
News NeuroRx, Relief, and Quantum Leap announce the inclusion of ZYESAMI in the I-SPY COVID-19 TrialNeuroRx, Inc. and RELIEF THERAPEUTICS Holding AG, and the Quantum Leap Healthcare Collaborative of San Francisco announce that NeuroRx and QLHC have signed a Clinical Trial Participation Agreement for the inclusion of ZYESAMI‚Ñ¢ in the I-SPY COVID-19 Clinical Trial. Quantum Leap is the sponsor of the I-SPY COVID ... |
| 1/11/2021 |
NeuroRx, Relief, and Quantum Leap announce the inclusion of ZYESAMI‚Ñ¢ (RLF-100‚Ñ¢: aviptadil) in the I-SPY COVID-19 Trial |
stocksnewsfeed.com |
... Äî NeuroRx, Inc. and RELIEF THERAPEUTICS Holding AG (SIX: RLF,OTCQB: RLFTF ) (‚ÄúRelief‚Äù), and the Quantum Leap Healthcare Collaborative (‚ÄúQuantum Leap‚Äù) of San Francisco announce that NeuroRx and QLHC have signed a Clinical Trial Participation Agreement for the inclusion of ZYESAMI‚Ñ¢ (RLF-100 TM : aviptadil) in the I-SPY COVID-19 Clinical Trial. Quantum Leap is the sponsor of the I-SPY COVID-19 Trial, a platform ... |
| 1/11/2021 |
NeuroRx, Relief, and Quantum Leap announce the inclusion of ZYESAMI‚Ñ¢ (RLF-100‚Ñ¢: aviptadil) in the I-SPY COVID-19 Trial-in-the-I-SPY-COVID-19-Trial?id=285702) |
otcmarkets.com |
... 11, 2021 /PRNewswire/ -- NeuroRx, Inc. and RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ("Relief"), and the Quantum Leap Healthcare Collaborative ("Quantum Leap") of San Francisco announce that NeuroRx and QLHC have signed a Clinical Trial Participation Agreement for the inclusion of ZYESAMI‚Ñ¢ (RLF-100 TM : aviptadil) in the I-SPY COVID-19 Clinical Trial. Quantum Leap is the sponsor of the I-SPY COVID-19 Trial, a platform ... |
| 1/11/2021 |
NeuroRx, Relief, and Quantum Leap announce the inclusion of ZYESAMI‚Ñ¢ (RLF-100‚Ñ¢: aviptadil) in the I-SPY COVID-19 Trial |
otcmarkets.com |
... 11, 2021 /PRNewswire/ -- NeuroRx, Inc. and RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ("Relief"), and the Quantum Leap Healthcare Collaborative ("Quantum Leap") of San Francisco announce that NeuroRx and QLHC have signed a Clinical Trial Participation Agreement for the inclusion of ZYESAMI‚Ñ¢ (RLF-100 TM : aviptadil) in the I-SPY COVID-19 Clinical Trial. Quantum Leap is the sponsor of the I-SPY COVID-19 Trial, a platform ... |
| 1/5/2021 |
Mednet Launches New and Expanded ePRO Functionality |
medicalalley.org |
Tags: ePRO , MedNetePRO Enhancements Improve User Experience and Enables Remote Clinical Trial Participation MINNEAPOLIS – December 16, 2020 – Today Mednet, a healthcare technology company, announced its latest software release featuring expanded electronic patient-reported outcomes (ePRO) capabilities. The new ePRO module is designed to increase patient engagement and further enable remote participation, an increasingly important requirement in the COVID-19 era, while also significantly improving the user experience ... |
| 1/4/2021 |
QYNAPSE Joins Decentralized Trials & Research Alliance (DTRA) To Democratize And Accelerate Clinical Trials |
aithority.com |
... trials and research. The “Decentralized Trials & Research Alliance ( DTRA ),” which launched December , 2020, plans to unite industry stakeholders, including healthcare companies, regulators, patient groups and research organizations with a singular mission to make clinical trial participation widely accessible by advancing policies, research practices and new technologies in decentralized clinical research.Recommended AI News: Insight Awarded Global SASE Partner of the Year from Palo Alto Networks“We are very excited ... |
| 10/13/2020 |
Impact of the COVID‐19 pandemic on telehealth research in cancer prevention and care: A call to sustain telehealth advances |
wiley.com |
... National Institutes of Health Revitalization Act of 1993 publicized the critical need to expand access to clinical trials to include women and racial and/or ethnic minorities. 3 Racial and ethnic inequities in cancer clinical trial participation are well established, with access barriers including competing demands (time and financial burden) and mistrust (fears of mistreatment, unknown research procedures, and unintended consequences). 4 - 6 Telehealth can ameliorate these long‐standing access ... |
| 9/15/2020 |
Impact of SARS-CoV-2 & COVID-19 on Volunteer Interest in Clinical Trial Participation, Upcoming Webinar Hosted by Xtalks |
PRWeb |
Impact of SARS-CoV-2 & COVID-19 on Volunteer Interest in Clinical Trial Participation, Upcoming Webinar Hosted by Xtalks Share Article In this free webinar, the featured speakers will discuss a strong COVID-19 risk mitigation plan, which is critical to maintaining safety, interest and participation and why limiting the entry of the virus into the research unit should include strict monitoring. Attendees will learn how the spread of the ... |
| 9/10/2020 |
Black Health Matters Launches Breast Cancer Initiative In research Clinical Study |
letlifehappen.com |
From: prnewswire.com Raising Awareness of Clinical Trial Participation Using Social Media Black Health Matters, the leading health and chronic disease management platform for African Americans will launch a social media campaign to raise awareness of breast cancer and clinical trial participation . This focus will introduce new content to be socialized on Facebook, Twitter and Instagram in a campaign that will speak to people of color with breast cancer. The campaign ... |
| 9/10/2020 |
Press Release: Illingworth Research Joins Avoca Quality Consortium |
illingworthresearch.com |
... Quality Consortium. This membership gives access to a wider network of over 120 pharma, biotech, and clinical service provider companies who all share a similar vision; to enhance and improve the patient experience of clinical trial participation . The consortium, founded in 2011, provides an exciting new space to share ideas, access training sessions and discuss industry developments. Illingworth is the first member of the consortium that can offer a truly ... |
| 9/3/2020 |
Genentech to Present New Data in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder at MSVirtual2020 |
Business Wire |
... Meeting 2019, which showed higher Ocrevus exposure was associated with lower B-cell levels and with less disability progression, without any associated impact on safety. Genentech is also deeply committed to addressing barriers to clinical trial participation and advancing inclusive research. The study design of the recently initiated CHIMES (CHaracterization of ocrelizumab In Minorities with multiplE Sclerosis) trial, an open-label, multi-center Phase IV study evaluating disease activity and ... |
| 9/3/2020 |
Genentech to Present New Data in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder at MSVirtual2020 |
Business Wire |
... Meeting 2019, which showed higher Ocrevus exposure was associated with lower B-cell levels and with less disability progression, without any associated impact on safety. Genentech is also deeply committed to addressing barriers to clinical trial participation and advancing inclusive research. The study design of the recently initiated CHIMES (CHaracterization of ocrelizumab In Minorities with multiplE Sclerosis) trial, an open-label, multi-center Phase IV study evaluating disease activity and ... |
| 9/3/2020 |
|
malvern-online.com |
... Meeting 2019, which showed higher Ocrevus exposure was associated with lower B-cell levels and with less disability progression, without any associated impact on safety. Genentech is also deeply committed to addressing barriers to clinical trial participation and advancing inclusive research. The study design of the recently initiated CHIMES (CHaracterization of ocrelizumab In Minorities with multiplE Sclerosis) trial, an open-label, multi-center Phase IV study evaluating disease activity and ... |
| 9/3/2020 |
Roche to present new data in multiple sclerosis and neuromyelitis optica spectrum disorder at MSVirtual2020 |
scientifictechnologynews.com |
... Annual Meeting 2019, which showed higher OCREVUS exposure was associated with lower B-cell levels and with greater control of disability progression, without impacting safety. Roche is also deeply committed to addressing barriers to clinical trial participation and advancing inclusive research. The study design of the recently initiated CHIMES (CHaracterisation of ocrelizumab In Minorities with multiplE Sclerosis) trial, an open-label, multi-centre Phase IV study evaluating disease activity and ... |
| 9/3/2020 |
Roche to present new data in multiple sclerosis and neuromyelitis optica spectrum disorder at MSVirtual2020 Swiss Stock Exchange:RO |
Globe Newswire |
... Annual Meeting 2019, which showed higher OCREVUS exposure was associated with lower B-cell levels and with greater control of disability progression, without impacting safety. Roche is also deeply committed to addressing barriers to clinical trial participation and advancing inclusive research. The study design of the recently initiated CHIMES (CHaracterisation of ocrelizumab In Minorities with multiplE Sclerosis) trial, an open-label, multi-centre Phase IV study evaluating disease activity and ... |
| 9/3/2020 |
Genentech to Present New Data in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder at MSVirtual2020 |
otcmarkets.com |
... Meeting 2019, which showed higher Ocrevus exposure was associated with lower B-cell levels and with less disability progression, without any associated impact on safety. Genentech is also deeply committed to addressing barriers to clinical trial participation and advancing inclusive research. The study design of the recently initiated CHIMES (CHaracterization of ocrelizumab In Minorities with multiplE Sclerosis) trial, an open-label, multi-center Phase IV study evaluating disease activity and ... |
| 9/3/2020 |
Roche to present new data in multiple sclerosis and neuromyelitis optica spectrum disorder at MSVirtual2020 |
roche.com |
... Annual Meeting 2019, which showed higher OCREVUS exposure was associated with lower B-cell levels and with greater control of disability progression, without impacting safety. Roche is also deeply committed to addressing barriers to clinical trial participation and advancing inclusive research. The study design of the recently initiated CHIMES (CHaracterisation of ocrelizumab In Minorities with multiplE Sclerosis) trial, an open-label, multi-centre Phase IV study evaluating disease activity and ... |